Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
32
SGMO Quote, Financials, Valuation and Earnings
Last price:
$0.53
Seasonality move
:
5.88%
Day range:
$0.43 - $0.50
52-week range:
$0.38 - $2.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.77x
P/B ratio:
26.91x
Volume:
7.4M
Avg. volume:
7.8M
1-year change:
-76.78%
Market cap:
$168M
Revenue:
$57.8M
EPS (TTM):
-$0.44
Analysts' Opinion
-
Consensus RatingSangamo Therapeutics, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.25, Sangamo Therapeutics, Inc. has an estimated upside of 550.91% from its current price of $0.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.50.
Fair Value
-
According to the consensus of 6 analysts, Sangamo Therapeutics, Inc. has 550.91% upside to fair value with a price target of $3.25 per share.
SGMO vs. S&P 500
-
Over the past 5 trading days, Sangamo Therapeutics, Inc. has overperformed the S&P 500 by 20.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sangamo Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sangamo Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sangamo Therapeutics, Inc. reported revenues of $581K.
Earnings Growth
-
Sangamo Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sangamo Therapeutics, Inc. reported earnings per share of -$0.11.
Enterprise value:
162.9M
EV / Invested capital:
5.14x
Price / LTM sales:
3.77x
EV / EBIT:
--
EV / Revenue:
4.96x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-2.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$25M
Return On Assets:
-111.37%
Net Income Margin (TTM):
-331.28%
Return On Equity:
-587.71%
Return On Invested Capital:
-242.33%
Operating Margin:
-6214.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $201.4M | $52.3M | $32.9M | $49.4M | $581K | |
| Gross Profit | $180.8M | $42.1M | $25M | $47.3M | -$1.3M | |
| Operating Income | -$107.3M | -$134.2M | -$110.3M | $8.5M | -$36.1M | |
| EBITDA | -$86.7M | -$124M | -$102.5M | $10.6M | -$34.2M | |
| Diluted EPS | -$1.44 | -$0.75 | -$0.44 | $0.04 | -$0.11 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $447.4M | $336.6M | $147.6M | $58.1M | $44.1M | |
| Total Assets | $772.4M | $593.9M | $219.7M | $111.3M | $88.6M | |
| Current Liabilities | $131.9M | $122.4M | $48.5M | $43.2M | $50.1M | |
| Total Liabilities | $366.4M | $284.8M | $84.8M | $72.1M | $82.4M | |
| Total Equity | $406M | $309.2M | $134.9M | $39.1M | $6.2M | |
| Total Debt | $36.1M | $39.7M | $35M | $27.7M | $25.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$231.4M | -$114.3M | -$76.2M | $11.8M | -$28.5M | |
| Cash From Investing | $158.4M | $73.9M | $1.2M | $233K | -$64K | |
| Cash From Financing | $34M | $21.6M | $62.9M | -$203K | $19.2M | |
| Free Cash Flow | -$257.3M | -$117.1M | -$76.4M | $11.6M | -$28.6M | |
SGMO
Sector
Market Cap
$168M
$28.4M
Price % of 52-Week High
17.58%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-30.13%
-1.32%
1-Year Price Total Return
-76.78%
-22.19%
Beta (5-Year)
1.407
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.44
200-day SMA
Sell
Level
$0.62
Bollinger Bands (100)
Sell
Level
0.47 - 0.63
Chaikin Money Flow
Sell
Level
-89.5M
20-day SMA
Buy
Level
$0.45
Relative Strength Index (RSI14)
Buy
Level
52.23
ADX Line
Buy
Level
24.27
Williams %R
Neutral
Level
-33.0411
50-day SMA
Sell
Level
$0.57
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
39.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-20.9101)
Sell
CA Score
(Annual)
Level (-4.1035)
Buy
Beneish M-Score
(Annual)
Level (-3.7829)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (7.8106)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Stock Forecast FAQ
In the current month, SGMO has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The SGMO average analyst price target in the past 3 months is $3.25.
-
Where Will Sangamo Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sangamo Therapeutics, Inc. share price will rise to $3.25 per share over the next 12 months.
-
What Do Analysts Say About Sangamo Therapeutics, Inc.?
Analysts are divided on their view about Sangamo Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sangamo Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Sangamo Therapeutics, Inc.'s Price Target?
The price target for Sangamo Therapeutics, Inc. over the next 1-year time period is forecast to be $3.25 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is SGMO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sangamo Therapeutics, Inc. is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of SGMO?
You can purchase shares of Sangamo Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sangamo Therapeutics, Inc. shares.
-
What Is The Sangamo Therapeutics, Inc. Share Price Today?
Sangamo Therapeutics, Inc. was last trading at $0.53 per share. This represents the most recent stock quote for Sangamo Therapeutics, Inc.. Yesterday, Sangamo Therapeutics, Inc. closed at $0.50 per share.
-
How To Buy Sangamo Therapeutics, Inc. Stock Online?
In order to purchase Sangamo Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SGMO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SGMO
Sector
P/E ratio
--
23.66x
PEG ratio
-0.04x
-0.01x
P/B ratio
26.91x
1.84x
Price / LTM sales
3.77x
1.60x
Growth Metrics
SGMO
Sector
Revenue growth
-98.82%
4.85%
Earnings growth
-362.1%
11.15%
Revenue (5-year growth)
-10.81%
6.45%
Earnings forecast
-$0.10
-$0.20
Profitability
SGMO
Sector
Profitability FY 2024
$48.4M
$3.6M
Return on invested capital
-242.33%
-30.98%
Return on assets
-111.37%
-27.62%
Return on equity
-587.71%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
16
Estimated Next Earnings Date
Feb
5
Balance Sheet
SGMO
Sector
Total cash
$30.5M
$27.2M
Short term investments
--
$25.7M
Total assets
$105.3M
$79.9M
Long term debt
$25.4M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
